Literature DB >> 8943038

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

P L Bergsagel1, M Chesi, E Nardini, L A Brents, S L Kirby, W M Kuehl.   

Abstract

In multiple myeloma, karyotopic 14q32 translocations have been identified at a variable frequency (10-60% in different studies). In the majority of cases, the partner chromosome has not been identified (14q+), and in the remaining cases, a diverse array of chromosomal partners has been implicated, with 11q13 being the most common. We developed a comprehensive Southern blot assay to identify and distinguish different kinds of immunoglobulin heavy chain (IgH) switch recombination events. Illegitimate switch recombination fragments (defined as containing sequences from only one switch region) are potential markers of translocation events into IgH switch regions and were identified in 15 of 21 myeloma cell lines, including seven of eight karyotyped lines that have no detectable 14q32 translocation. From all nine lines or tumor samples analyzed further, cloned illegitimate switch recombination fragments were confirmed to be IgH switch translocation breakpoints. In three of these cases, the translocation breakpoint was shown to be present in the primary tumor. These translocation breakpoints involve six chromosomal loci: 4p16.3 (two lines and the one tumor); 6; 8q24.13; 11q13.3 (in three lines); 16q23.1; and 21q22.1. We suggest that translocations into the IgH locus (i) are frequent (karyotypic 14q32 translocations and/or illegitimate switch recombination fragments are present in primary tumor samples and in 19 of 21 lines that we have analyzed); (ii) occur mainly in switch regions; and (iii) involve a diverse but nonrandom array (i.e., frequently 11q13 or 4p16) of chromosomal partners. This appears to be the most frequent genetic abnormality in multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943038      PMCID: PMC19472          DOI: 10.1073/pnas.93.24.13931

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  44 in total

1.  Dysregulation of cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines.

Authors:  M Chesi; P L Bergsagel; L A Brents; C M Smith; D S Gerhard; W M Kuehl
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth.

Authors:  Y Okuno; T Takahashi; A Suzuki; S Ichiba; K Nakamura; M Fukumoto; T Okada; H Okada; H Imura
Journal:  Leukemia       Date:  1991-07       Impact factor: 11.528

3.  Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.

Authors:  Y Matsuoka; G E Moore; Y Yagi; D Pressman
Journal:  Proc Soc Exp Biol Med       Date:  1967 Aug-Sep

4.  Immunoglobulin D switching can occur through homologous recombination in human B cells.

Authors:  M B White; C J Word; C G Humphries; F R Blattner; P W Tucker
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

5.  Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.

Authors:  K Nilsson; H Bennich; S G Johansson; J Pontén
Journal:  Clin Exp Immunol       Date:  1970-10       Impact factor: 4.330

6.  Genotypic characterization of centrocytic lymphoma: frequent rearrangement of the chromosome 11 bcl-1 locus.

Authors:  M E Williams; C D Westermann; S H Swerdlow
Journal:  Blood       Date:  1990-10-01       Impact factor: 22.113

7.  Establishment and characterization of two human myeloma cell lines secreting kappa light chains.

Authors:  O Eton; D A Scheinberg; A N Houghton
Journal:  Leukemia       Date:  1989-10       Impact factor: 11.528

8.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

9.  Role of interleukin-6 in the proliferation of human multiple myeloma cell lines OCI-My 1 to 7 established from patients with advanced stage of the disease.

Authors:  J K Hitzler; H Martinez-Valdez; D B Bergsagel; M D Minden; H A Messner
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

10.  Establishment of five human myeloma cell lines.

Authors:  M Namba; T Ohtsuki; M Mori; A Togawa; H Wada; T Sugihara; Y Yawata; T Kimoto
Journal:  In Vitro Cell Dev Biol       Date:  1989-08
View more
  76 in total

1.  Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authors:  Dharminder Chauhan; Madhavi Bandi; Ajita V Singh; Arghya Ray; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2011-09-26       Impact factor: 6.998

Review 2.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

3.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

4.  Establishment of CD5 and CD10 double-positive mature B-cell line, WILL1, showing complex 8q24 translocation involving 14q32 and 6q27.

Authors:  Shima Uneda; Minako Gotoh; Takashi Sonoki; Kazuhiro Nishida; Yasushi Nakamura; Miwa Kurimoto; Nobuyoshi Hanaoka; Hiroshi Matsuoka; Masafumi Taniwaki; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2008-10-30       Impact factor: 2.490

Review 5.  Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma.

Authors:  Brendan M Weiss; W Michael Kuehl
Journal:  Expert Rev Hematol       Date:  2010-04       Impact factor: 2.929

6.  Rapid detection of IgH/BCL2 rearrangement in follicular lymphoma by interphase fluorescence in situ hybridization with bacterial artificial chromosome probes.

Authors:  Feng Jiang; Fan Lin; Roger Price; Jun Gu; L Jeffrey Medeiros; Hua Z Zhang; Su-Su Xie; Nancy P Caraway; Ruth L Katz
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

7.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

Review 8.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

9.  Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Authors:  Dharminder Chauhan; Ajita V Singh; Bryan Ciccarelli; Paul G Richardson; Michael A Palladino; Kenneth C Anderson
Journal:  Blood       Date:  2009-11-13       Impact factor: 22.113

10.  The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor.

Authors:  Jotin Marango; Manabu Shimoyama; Hitomi Nishio; Julia A Meyer; Dong-Joon Min; Andres Sirulnik; Yolanda Martinez-Martinez; Marta Chesi; P Leif Bergsagel; Ming-Ming Zhou; Samuel Waxman; Boris A Leibovitch; Martin J Walsh; Jonathan D Licht
Journal:  Blood       Date:  2007-12-21       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.